- Home
- VRSK vs ARGX Comparison
VRSK vs ARGX Comparison
Compare VRSK & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRSK
- ARGX
- Stock Information
- Founded
- VRSK 1971
- ARGX 2008
- Country
- VRSK United States
- ARGX Netherlands
- Employees
- VRSK N/A
- ARGX N/A
- Industry
- VRSK Business Services
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRSK Consumer Discretionary
- ARGX Health Care
- Exchange
- VRSK Nasdaq
- ARGX Nasdaq
- Market Cap
- VRSK 41.7B
- ARGX 40.4B
- IPO Year
- VRSK 2009
- ARGX 2017
- Fundamental
- Price
- VRSK $295.11
- ARGX $644.48
- Analyst Decision
- VRSK Hold
- ARGX Strong Buy
- Analyst Count
- VRSK 10
- ARGX 20
- Target Price
- VRSK $289.80
- ARGX $653.11
- AVG Volume (30 Days)
- VRSK 623.8K
- ARGX 229.4K
- Earning Date
- VRSK 02-26-2025
- ARGX 02-27-2025
- Dividend Yield
- VRSK 0.53%
- ARGX N/A
- EPS Growth
- VRSK 92.59
- ARGX N/A
- EPS
- VRSK 6.41
- ARGX N/A
- Revenue
- VRSK $2,823,300,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- VRSK $9.53
- ARGX $73.18
- Revenue Next Year
- VRSK $7.46
- ARGX $55.26
- P/E Ratio
- VRSK $45.58
- ARGX N/A
- Revenue Growth
- VRSK 7.16
- ARGX 85.56
- 52 Week Low
- VRSK $217.34
- ARGX $349.86
- 52 Week High
- VRSK $296.94
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- VRSK 61.00
- ARGX 49.33
- Support Level
- VRSK $291.06
- ARGX $637.15
- Resistance Level
- VRSK $296.92
- ARGX $652.23
- Average True Range (ATR)
- VRSK 4.44
- ARGX 12.63
- MACD
- VRSK -0.02
- ARGX -1.94
- Stochastic Oscillator
- VRSK 85.65
- ARGX 30.64
About VRSK Verisk Analytics Inc.
Verisk Analytics is the leading provider of statistical, actuarial, and underwriting data for the United States' property and casualty insurance industry. Verisk leverages a vast contributory database and proprietary data assets to develop analytical tools helping insurance providers to better assess and price risk, achieve operational efficiency and optimize claim settlement processes. While Verisk also offers tools to quantify costs after loss events occur and to detect fraudulent activity, it is expanding into adjacent markets of life insurance, marketing, and non-US operations.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.